Clinical Trials Browser

INDUSTRY × Crizotinib × Dermatologic × Clear all

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

Uveal Melanoma, Melanoma

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms